[
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript",
    "summary": "Eli Lilly and Company (LLY) Citi Annual Global Healthcare Conference 2025 December 2, 2025 10:30 AM ESTCompany ParticipantsIlya Yuffa - Executive VP and...",
    "url": "https://finnhub.io/api/news?id=e46434fe3f5e18b96f857f5c7f268d44616f1643097c4f4b816ffb3fa9012883",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764683007,
      "headline": "Eli Lilly and Company (LLY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript",
      "id": 137664391,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly and Company (LLY) Citi Annual Global Healthcare Conference 2025 December 2, 2025 10:30 AM ESTCompany ParticipantsIlya Yuffa - Executive VP and...",
      "url": "https://finnhub.io/api/news?id=e46434fe3f5e18b96f857f5c7f268d44616f1643097c4f4b816ffb3fa9012883"
    }
  },
  {
    "ts": null,
    "headline": "XLV: The Simple Case For Overweighting U.S. Health Care",
    "summary": "Discover why XLV Health Care ETF may offer strong growth, low beta, and momentum.",
    "url": "https://finnhub.io/api/news?id=855c26666a002d7a79c5c67f7d2902ba7688f3d5dc1628720974bebf4d809052",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764676597,
      "headline": "XLV: The Simple Case For Overweighting U.S. Health Care",
      "id": 137663711,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/467786549/image_467786549.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover why XLV Health Care ETF may offer strong growth, low beta, and momentum.",
      "url": "https://finnhub.io/api/news?id=855c26666a002d7a79c5c67f7d2902ba7688f3d5dc1628720974bebf4d809052"
    }
  },
  {
    "ts": null,
    "headline": "Abemaciclib Research Report 2025: Eli Lilly and Company Dominates the $1.6 Billion Market - Long-term Forecasts to 2029 and 2034",
    "summary": "Key market opportunities for abemaciclib include growing demand for targeted therapies in oncology, advancements in combination therapies with immuno-oncology, and integration of personalized medicine. Emerging markets in Asia-Pacific, expanded cancer treatment access, and innovations in therapy delivery methods further bolster growth. Abemaciclib Market Abemaciclib Market Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The \"Abemaciclib Market Report 2025\" report has been added to ResearchAndMarkets.c",
    "url": "https://finnhub.io/api/news?id=746ae3f4c23033659a2a86971943a81937d8224d992b5bdc777e0822ba9f45ad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764666600,
      "headline": "Abemaciclib Research Report 2025: Eli Lilly and Company Dominates the $1.6 Billion Market - Long-term Forecasts to 2029 and 2034",
      "id": 137662185,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Key market opportunities for abemaciclib include growing demand for targeted therapies in oncology, advancements in combination therapies with immuno-oncology, and integration of personalized medicine. Emerging markets in Asia-Pacific, expanded cancer treatment access, and innovations in therapy delivery methods further bolster growth. Abemaciclib Market Abemaciclib Market Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The \"Abemaciclib Market Report 2025\" report has been added to ResearchAndMarkets.c",
      "url": "https://finnhub.io/api/news?id=746ae3f4c23033659a2a86971943a81937d8224d992b5bdc777e0822ba9f45ad"
    }
  },
  {
    "ts": null,
    "headline": "SNPG: A New ETF Perfect For Retirees - S&P 500 Exposure, Growth, And Outperformance Potential",
    "summary": "Xtrackers S&P 500 Growth Scored & Screened ETF offers a differentiated, growth-focused alternative to traditional S&P 500 index funds. Learn more about SNPG ETF here.",
    "url": "https://finnhub.io/api/news?id=853c8431c31560e91bc4d3dc218e4c7bac6fd7ff32dedf33c7dfaf994eae4fe8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764659700,
      "headline": "SNPG: A New ETF Perfect For Retirees - S&P 500 Exposure, Growth, And Outperformance Potential",
      "id": 137661408,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2234875955/image_2234875955.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Xtrackers S&P 500 Growth Scored & Screened ETF offers a differentiated, growth-focused alternative to traditional S&P 500 index funds. Learn more about SNPG ETF here.",
      "url": "https://finnhub.io/api/news?id=853c8431c31560e91bc4d3dc218e4c7bac6fd7ff32dedf33c7dfaf994eae4fe8"
    }
  },
  {
    "ts": null,
    "headline": "Morgan Stanley Bullish on Eli Lilly and Company (LLY)",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best dividend stocks to buy according to hedge funds. On November 23, Morgan Stanley analyst Terence Flynn maintained a Buy call on Eli Lilly, along with a price target of $1,290. In a different corporate update, dated November 24, Eli Lilly reported that it will present […]",
    "url": "https://finnhub.io/api/news?id=065491ec9a3b68dcb9700835fadc1bc906860e3e0b5de4dc3dc2e0f2455e2ed0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764655612,
      "headline": "Morgan Stanley Bullish on Eli Lilly and Company (LLY)",
      "id": 137658830,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best dividend stocks to buy according to hedge funds. On November 23, Morgan Stanley analyst Terence Flynn maintained a Buy call on Eli Lilly, along with a price target of $1,290. In a different corporate update, dated November 24, Eli Lilly reported that it will present […]",
      "url": "https://finnhub.io/api/news?id=065491ec9a3b68dcb9700835fadc1bc906860e3e0b5de4dc3dc2e0f2455e2ed0"
    }
  }
]